Antibody-Based Immunotherapeutic Agents for Treatment of Non-Hodgkin Lymphoma

被引：0

作者：

Park, Steven I. ^{[1
]}

Richards, Krsty L. ^{[1
]}

机构：

[1] Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Hematol & Oncol, Chapel Hill, NC 27599 USA

来源：

LABMEDICINE | 2013年 / 44卷 / 02期

基金：

美国国家卫生研究院;

关键词：

hematology; blood banking; transfusion medicine; immunology; ANTI-CD20; MONOCLONAL-ANTIBODY; CHRONIC LYMPHOCYTIC-LEUKEMIA; PROGRESSION-FREE SURVIVAL; IODINE I-131 TOSITUMOMAB; MULTICENTER PHASE-II; REFRACTORY LOW-GRADE; B-CELL LYMPHOMA; FOLLICULAR LYMPHOMA; ELDERLY-PATIENTS; ZANOLIMUMAB HUMAX-CD4;

D O I：

10.1309/LMWAT6W5LT3TIPVX

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Antibody-based immunotherapeutic agents have emerged as important treatment options for non-Hodgkin lymphoma. Recent data suggest that use of these agents not only induces high response rates but also results in improved survival when combined with conventional chemotherapy in patients with non-Hodgkin lymphoma. As a result, antibody-based immunotherapy has changed lymphoma therapy considerably and dramatically impacted the management of patients with non-Hodgkin lymphoma. Several unmodified and radiolabeled antibodies, as well as antibody-drug conjugates, have been approved by the United States Food and Drug Administration (FDA) for treatment of non-Hodgkin lymphoma. Also, more promising antibodies that target other epitopes are being developed in preclinical and clinical studies. This review presents the latest information on antibody-based innmunotherapeutic agents for treatment of non-Hodgkin lymphoma in various clinical settings and discusses current clinical and laboratory guidelines for the use of antibodies for treatment of different subtypes of non-Hodgkin lymphoma.

引用

页码：108 / 113

页数：6

共 61 条

[1] Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study [J].

Advani, Anjali ;

Coiffier, Bertrand ;

Czuczman, Myron S. ;

Dreyling, Martin ;

Foran, James ;

Gine, Eva ;

Gisselbrecht, Christian ;

Ketterer, Nicolas ;

Nasta, Sunita ;

Rohatiner, Ama ;

Schmidt-Wolf, Ingo G. H. ;

Schuler, Martin ;

Sierra, Jorge ;

Smith, Mitchell R. ;

Verhoef, Gregor ;

Winter, Jane N. ;

Boni, Joseph ;

Vandendries, Erik ;

Shapiro, Mark ;

Fayad, Luis .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) :2085-2093

[2] New approach to classifying non-hodgkin's lymphomas: Clinical features of the major histologic subtypes [J].

Armitage, JO ;

Weisenburger, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2780-2795

[3] Tumor regression in cancer patients by very low doses of a T cell-engaging antibody [J].

Bargou, Ralf ;

Leo, Eugen ;

Zugmaier, Gerhard ;

Klinger, Matthias ;

Goebeler, Mariele ;

Knop, Stefan ;

Noppeney, Richard ;

Viardot, Andreas ;

Hess, Georg ;

Schuler, Martin ;

Einsele, Hermann ;

Brandl, Christian ;

Wolf, Andreas ;

Kirchinger, Petra ;

Klappers, Petra ;

Schmidt, Margit ;

Riethmueller, Gert ;

Reinhardt, Carsten ;

Baeuerle, Patrick A. ;

Kufer, Peter .

SCIENCE, 2008, 321 (5891) :974-977

[4] Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab [J].

Bennett, JM ;

Kaminski, MS ;

Leonard, JP ;

Vose, JM ;

Zelenetz, AD ;

Knox, SJ ;

Horning, S ;

Press, OW ;

Radford, JA ;

Kroll, SM ;

Capizzi, RL .

BLOOD, 2005, 105 (12) :4576-4582

[5] CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) [J].

Boehme, Volkmar ;

Schmitz, Norbert ;

Zeynalova, Samira ;

Loeffler, Markus ;

Pfreundschuh, Michael .

BLOOD, 2009, 113 (17) :3896-3902

[6] Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) [J].

Byrd, JC ;

Peterson, BL ;

Morrison, VA ;

Park, K ;

Jacobson, R ;

Hoke, E ;

Vardiman, JW ;

Rai, K ;

Schiffer, CA ;

Larson, RA .

BLOOD, 2003, 101 (01) :6-14

[7] Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011 [J].

Byrd, JC ;

Rai, K ;

Peterson, BL ;

Appelbaum, FR ;

Morrison, VA ;

Kolitz, JE ;

Shepherd, L ;

Hines, JD ;

Schiffer, CA ;

Larson, RA .

BLOOD, 2005, 105 (01) :49-53

[8] Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia [J].

Byrd, John C. ;

Kipps, Thomas J. ;

Flinn, Ian W. ;

Castro, Januaro ;

Lin, Thomas S. ;

Wierda, William ;

Heerema, Nyla ;

Woodworth, James ;

Hughes, Steve ;

Tangri, Shabnam ;

Harris, Sarah ;

Wynne, Dee ;

Molina, Arturo ;

Leigh, Bryan ;

O'Brien, Susan .

BLOOD, 2010, 115 (03) :489-495

[9]

Castillo J, 2009, EXPERT OPIN INV DRUG, V18, P491, DOI [10.1517/13543780902832679 , 10.1517/13543780902832679]

[10] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

← 1 2 3 4 5 6 7 →